Evidence map›Paper›PMID 31889962›Full record

ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2019

Expression of COX-1, COX-2, 5-LOX and

Monique Vorsprach, Christoph Arens, Stephan Knipping, Dörte Jechorek, Sabine Stegemann-Koniszewski, Eva Lücke, Jens Schreiber

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Low Prostaglandin EJournal of clinical medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Monique Vorsprach1Departmemt of Pneumology, University Hospital Magdeburg, Medical Faculty, Otto-von-Guericke-University, Leipziger Straße 44, 39120 Magdeburg, Germany.
Christoph Arens2Department of Otorhinolaryngology, Head- and Neck Surgery, University Hospital Magdeburg, Medical Faculty, Otto-von-Guericke-University, Leipziger Straße 44, 39120 Magdeburg, Germany.
Stephan Knipping3Department of Otorhinolaryngology, Head- and Neck Surgery, Plastical Surgery, Dessau Medical Center, Martin-Luther-University Halle, Auenweg 38, 06847 Dessau, Germany.
Dörte Jechorek4Department of Pathology, University Hospital Magdeburg, Medical Faculty, Otto-von-Guericke-University, Leipziger Straße 44, 39120 Magdeburg, Germany.
Sabine Stegemann-Koniszewski1Departmemt of Pneumology, University Hospital Magdeburg, Medical Faculty, Otto-von-Guericke-University, Leipziger Straße 44, 39120 Magdeburg, Germany.
Eva Lücke1Departmemt of Pneumology, University Hospital Magdeburg, Medical Faculty, Otto-von-Guericke-University, Leipziger Straße 44, 39120 Magdeburg, Germany.
Jens Schreiber1Departmemt of Pneumology, University Hospital Magdeburg, Medical Faculty, Otto-von-Guericke-University, Leipziger Straße 44, 39120 Magdeburg, Germany.
University Hospital Magdeburg · DEMartin Luther University Halle-Wittenberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAspirin exacerbated respiratory disease (AERD) is a disease of the upper and lower airways. It is characterized by severe asthma, chronic sinusitis with nasal polyps (CRSwNP) and intolerance towards nonsteroidal analgesics (NSAR). Arachidonic acid (AA) metabolites play an important role in the pathogenesis of AERD. It is still unknown, whether metabolism of AA is comparable between the upper and lower airways as well as between patients with and without NSAR intolerance.

objectiveWe sought to analyze differences in the expression of cyclooxygenases type 1 and 2 (COX-1, COX-2), arachidonate 5-lipoxygenase (5-LOX) and cysteinyl leukotriene receptor type 2 (

methodsTissue biopsies from nasal polyps and bronchial mucosa were obtained during surgical treatment of nasal polyps by endonasal functional endoscopic sinus surgery (FESS) under general anesthesia from intubated patients. Immunohistochemistry was used to analyze the expression of COX-1, COX-2, 5-LOX and

resultsWe observed a stronger expression of 5-LOX and

conclusionsThe AA-metabolizing enzymes and the

Indexed as

Arachidonic acidAspirin exacerbated respiratory diseaseAsthmaCyclooxygenasesLeukotrienesLipoxygenasesNasal polyps

Identifiers

PMID31889962
PMCPMC6933683
OpenAlexW2996958890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.